Published in Antimicrob Agents Chemother on November 01, 1980
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors. Antimicrob Agents Chemother (1983) 5.10
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother (1986) 4.51
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother (1982) 3.84
In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs. Antimicrob Agents Chemother (1983) 3.70
Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother (1987) 3.47
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother (1986) 3.21
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother (1997) 3.17
In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother (1991) 2.93
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother (1982) 2.58
Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother (1988) 2.52
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother (1998) 2.43
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother (1990) 2.35
Antibiotic combinations: should they be tested? Clin Microbiol Rev (1988) 2.34
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother (1992) 2.32
Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother (1991) 2.31
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother (2000) 2.27
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother (1986) 2.26
Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother (1991) 2.18
In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother (1988) 2.09
Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother (1997) 2.09
In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother (1994) 2.03
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother (1990) 1.98
Variables in demonstrating methicillin tolerance in Staphylococcus aureus strains. Antimicrob Agents Chemother (1982) 1.97
Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase. Antimicrob Agents Chemother (1990) 1.96
In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338. Antimicrob Agents Chemother (1989) 1.94
Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev (1992) 1.84
In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother (1988) 1.82
Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother (1991) 1.81
In vitro activity of sparfloxacin. Antimicrob Agents Chemother (1991) 1.79
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother (1986) 1.79
Role of beta-lactamase and different testing conditions in oxacillin-borderline-susceptible staphylococci. Antimicrob Agents Chemother (1988) 1.78
Comparative in vitro activity of a new quinolone, AM-1091. Antimicrob Agents Chemother (1989) 1.78
Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother (1987) 1.78
In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol (1992) 1.75
In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob Agents Chemother (1988) 1.75
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Antimicrob Agents Chemother (1986) 1.74
In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum. Antimicrob Agents Chemother (1992) 1.71
Quantitative susceptibility test methods in major United States medical centers. Antimicrob Agents Chemother (1981) 1.70
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother (2007) 1.68
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother (1989) 1.67
Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother (1995) 1.66
Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother (1989) 1.62
Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev (2004) 1.60
In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother (1986) 1.60
Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother (1998) 1.60
Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains. Antimicrob Agents Chemother (1987) 1.58
Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1984) 1.57
Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci. Antimicrob Agents Chemother (1989) 1.56
In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones. Antimicrob Agents Chemother (1988) 1.56
In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1988) 1.53
Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother (1986) 1.49
Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother (1988) 1.48
In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother (1994) 1.48
Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother (1989) 1.47
Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin. Antimicrob Agents Chemother (1986) 1.43
Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother (1985) 1.42
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother (1999) 1.41
Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci. Antimicrob Agents Chemother (1982) 1.41
Efficacy of oxacillin and ampicillin-sulbactam combination in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother (1990) 1.40
Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-formimidoyl thienamycin against beta-lactamase-producing, carbenicillin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 1.38
Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob Agents Chemother (1990) 1.38
Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother (2002) 1.36
Novel antimicrobial peptides derived from human immunodeficiency virus type 1 and other lentivirus transmembrane proteins. Antimicrob Agents Chemother (1997) 1.35
Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother (1988) 1.35
Problems in in vitro determination of antibiotic tolerance in clinical isolates. Antimicrob Agents Chemother (1986) 1.32
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother (1994) 1.30
In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin. Antimicrob Agents Chemother (1991) 1.28
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. Antimicrob Agents Chemother (1988) 1.28
Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci. Antimicrob Agents Chemother (1994) 1.27
In vitro activities of two glycylcyclines. Antimicrob Agents Chemother (1994) 1.27
Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother (1997) 1.27
In vitro activity of OPC-17116. Antimicrob Agents Chemother (1992) 1.26
Evaluation of oxacillin tolerance in Staphylococcus aureus by a novel method. Antimicrob Agents Chemother (1985) 1.26
Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother (2000) 1.24
In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother (2010) 1.23
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin. Antimicrob Agents Chemother (1993) 1.23
Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother (1987) 1.23
Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob Agents Chemother (1989) 1.23
Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother (1990) 1.21
In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother (2002) 1.21
In vitro activity of CGP 31608, a new penem. Antimicrob Agents Chemother (1987) 1.21
Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother (1992) 1.20
pH-dependent oxacillin tolerance of Staphylococcus aureus. Antimicrob Agents Chemother (1983) 1.19
Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother (1998) 1.19
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.19
In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli. Antimicrob Agents Chemother (1989) 1.18
Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum. Antimicrob Agents Chemother (1987) 1.18
MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother (1990) 1.18
Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin. Antimicrob Agents Chemother (1986) 1.17
In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother (1997) 1.17
In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother (1992) 1.17
Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother (1992) 1.17
Comparative in vitro antibiotic resistance of surface-colonizing coagulase-negative staphylococci. Antimicrob Agents Chemother (1989) 1.14
Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1983) 1.14
A new type of penicillin resistance of Staphylococcus aureus. Lancet (1977) 9.15
Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin. Antimicrob Agents Chemother (1976) 6.26
In-vitro methods for determining minimal lethal concentrations of antimicrobial agents. Am J Clin Pathol (1979) 4.66
Incidence and characteristics of antibiotic-tolerant strains of Staphylococcus aureus. Antimicrob Agents Chemother (1978) 4.46
Susceptibility of clinical isolates of Staphylococcus aureus to killing by oxacillin. Can J Microbiol (1975) 4.37
Medium-dependent variation in bactericidal activity of antibiotics against susceptible Staphylococcus aureus. Antimicrob Agents Chemother (1978) 4.28
Antibiotic-tolerant Staphylococcus aureus. J Antimicrob Chemother (1978) 3.76
Tolerance in Staphylococcus aureus. Lancet (1979) 3.60
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
A case of phaeohyphomycosis caused by a new species of Phialophora. Mycologia (1974) 3.48
Risks to health care workers in developing countries. N Engl J Med (2001) 3.37
Rates of needle-stick injury caused by various devices in a university hospital. N Engl J Med (1988) 2.88
Controlled environment vitrification system: an improved sample preparation technique. J Electron Microsc Tech (1988) 2.70
Phagocytic and bacterial properties of normal human monocytes. J Clin Invest (1974) 2.65
Occupational exposure to blood among medical students. N Engl J Med (1996) 2.31
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis (2001) 2.25
Mechanism of lethal effect of human serum upon Leishmania donovani. J Immunol (1980) 2.08
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis (1992) 1.99
Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr (2000) 1.98
Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes. Infect Immun (1988) 1.89
Amphotericin B activation of human genes encoding for cytokines. J Infect Dis (1998) 1.77
The immunobiology of leishmaniasis. Rev Infect Dis (1983) 1.76
Rochalimaea's role in cat scratch disease and bacillary angiomatosis. Ann Intern Med (1993) 1.73
Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes. J Immunol (1981) 1.65
Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis (1996) 1.60
An atypical subcutaneous infection associated with acquired immune deficiency syndrome. Am J Clin Pathol (1983) 1.59
Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation (1979) 1.55
Health advice for international travel. Ann Intern Med (1988) 1.51
Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med (1984) 1.50
Interaction of human leukocytes and Entamoeba histolytica. Killing of virulent amebae by the activated macrophage. J Clin Invest (1985) 1.49
Measles prophylaxis for international travel. Ann Intern Med (1989) 1.48
Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest (1993) 1.47
Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. J Immunol (1986) 1.47
Advantages and complications of umbilical artery catheterization in the newborn. Pediatrics (1968) 1.39
Antibiotic combinations in the treatment of experimental Staphylococcus aureus infection. J Infect Dis (1975) 1.39
Staphylococcal beta-lactamase and efficacy of beta-lactam antibiotics: in vitro and in vivo evaluation. J Infect Dis (1983) 1.38
Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1995) 1.37
Survivorship patterns in the posthospital phase of myocardial infarction. Circulation (1979) 1.34
Early histopathology of experimental infection with Leishmania donovani in hamsters. J Parasitol (1987) 1.32
An urban outbreak of visceral leishmaniasis in Natal, Brazil. Trans R Soc Trop Med Hyg (1995) 1.32
Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis (2000) 1.31
Effect of in vitro virus infection on response of human monocytes and lymphocytes to mitogen stimulation. J Immunol (1978) 1.30
Nocardial infections in renal transplant recipients. Medicine (Baltimore) (1989) 1.30
Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani. Science (1982) 1.30
Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med (1995) 1.29
Giardia lamblia infection of suckling mice. J Infect Dis (1983) 1.29
Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up. Clin Infect Dis (2000) 1.28
Clinical and laboratory studies into the pathogenesis of malacoplakia. J Clin Pathol (1976) 1.27
Characterization of a major peritrophic membrane protein, peritrophin-44, from the larvae of Lucilia cuprina. cDNA and deduced amino acid sequences. J Biol Chem (1996) 1.21
Hyperthermia and human leukocyte functions: effects on response of lymphocytes to mitogen and antigen and bactericidal capacity of monocytes and neutrophils. Infect Immun (1977) 1.20
Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani. J Immunol (1982) 1.19
Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases. Ann Intern Med (1985) 1.18
Role of the Vi antigen of Salmonella typhi in resistance to host defense in vitro. J Lab Clin Med (1986) 1.18
Antileishmanial activity of chlorpromazine. Antimicrob Agents Chemother (1984) 1.17
Niclosamide therapy for tapeworm infections. Ann Intern Med (1985) 1.17
The nitroblue tetrazolium reduction test versus conventional hematology in the diagnosis of bacterial infection. N Engl J Med (1974) 1.16
Serious infections with Edwardsiella tarda. A case report and review of the literature. Arch Intern Med (1989) 1.14
Immunization against Lyme disease--an important first step. N Engl J Med (1998) 1.12
Inhibition by ketoconazole of mitogen-induced DNA synthesis and cholesterol biosynthesis in lymphocytes. Antimicrob Agents Chemother (1983) 1.12
Vaccination against Boophilus microplus: localization of antigens on tick gut cells and their interaction with the host immune system. Exp Appl Acarol (1989) 1.12
Acidosis of synovial fluid correlates with synovial fluid leukocytosis. Am J Med (1978) 1.12
Infective endocarditis and access site infections in patients on hemodialysis. Medicine (Baltimore) (1976) 1.11
Interaction of Leishmania donovani promastigotes with human monocyte-derived macrophages: parasite entry, intracellular survival, and multiplication. Infect Immun (1981) 1.10
In situ detection of PCR-amplified HIV-1 nucleic acids in lymph nodes and peripheral blood in patients with asymptomatic HIV-1 infection and advanced-stage AIDS. J Acquir Immune Defic Syndr (1994) 1.09
Intravenous itraconazole. Ann Pharmacother (2001) 1.08
Increasing ICU staff handwashing: effects of education and group feedback. Infect Control Hosp Epidemiol (1990) 1.08
Universal precautions: still missing the point on needlesticks. Infect Control Hosp Epidemiol (1991) 1.07
Increasing handwashing in an intensive care unit. Infect Control (1986) 1.06
Bordetella extracytoplasmic adenylate cyclase: actions as a bacterial toxin. Dev Biol Stand (1985) 1.06
Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J Infect Dis (1983) 1.05
Immunization of cattle against Boophilus microplus using extracts derived from adult female ticks: effects of induced immunity on tick populations. Int J Parasitol (1986) 1.05
Evaluation of antibody responses in American visceral leishmaniasis by ELISA and immunoblot. Mem Inst Oswaldo Cruz (1990) 1.05
A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) (2000) 1.04
Digitalis-associated cardiac mortality after myocardial infarction. Circulation (1981) 1.04
Validation of Bayesian kriging of arsenic, chromium, lead, and mercury surface soil concentrations based on internode sampling. Environ Sci Technol (2009) 1.03
Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum. J Immunol (1984) 1.03
Tuberculous mastitis. Chest (1990) 1.03
Itraconazole in antifungal therapy. Ann Pharmacother (1992) 1.02
Differential survival of Leishmania donovani amastigotes in human monocytes. J Immunol (1983) 1.02
Insect chitin synthase cDNA sequence, gene organization and expression. Eur J Biochem (2000) 1.02
Varicella zoster virus transverse myelitis without cutaneous rash. Am J Med (1990) 1.00
Recapping used needles: is it worse than the alternative? J Infect Dis (1990) 0.99
Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro. Antimicrob Agents Chemother (1992) 0.99
Pilot study comparing the salivary cationic protein concentrations in healthy adults and AIDS patients: correlation with antifungal activity. J Acquir Immune Defic Syndr (1992) 0.99
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci U S A (1995) 0.99
Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother (1992) 0.98
Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1997) 0.97
Polymorphonuclear leukocyte, monocyte, and macrophage bactericidal function in patients with Hodgkin's disease. J Lab Clin Med (1976) 0.97
Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J Infect Dis (1993) 0.97
Postmarketing surveillance of new drugs: I. Review of objectives and methodology. J Clin Pharmacol (1979) 0.96
Praziquantel: a major advance in anthelminthic therapy. Ann Intern Med (1983) 0.96
Acquired immunodeficiency syndrome-related visceral leishmaniasis presenting in a pleural effusion. Chest (1993) 0.96
Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis (1991) 0.95
Susceptibility of Bordetella species to growth inhibition and killing by chlorpromazine. Antimicrob Agents Chemother (1983) 0.94
Susceptibility of Campylobacter jejuni to strain-specific bactericidal activity in sera of infected patients. Infect Immun (1986) 0.94
Secretory immunoglobulin A antibodies to the galactose-inhibitable adherence protein in the saliva of patients with amebic liver disease. Am J Trop Med Hyg (1994) 0.93
Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann Intern Med (1981) 0.93
Mitogen responses and interferon production after exposure of human macrophages to infectious and inactivated influenza viruses. J Med Virol (1980) 0.93
Lectin binding by Giardia lamblia. Infect Immun (1981) 0.93
Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase. J Virol Methods (1993) 0.93
Convulsions in the first three years of life. Med J Aust (1977) 0.93
Reciprocal relationships between undernutrition and the parasitic disease visceral leishmaniasis. Rev Infect Dis (1986) 0.92
Hereditary deficiency of the fifth component of complement in man. II. Biological properties of C5-deficient human serum. J Clin Invest (1976) 0.92